000908.SHE Hunan Jingfeng Pharmaceutical
- Market cap
- CNY 9.26B
- P/E
- -
- P/B
- 4.20x
- ROE
- 0.1%
- Dividend yield
- 0.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000908.SHE undervalued?
Graham numberThe Graham number of Hunan Jingfeng Pharmaceutical cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hunan Jingfeng Pharmaceutical fundamental analysis
No fundamental analysis for Hunan Jingfeng Pharmaceutical yet.
Hunan Jingfeng Pharmaceutical stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hunan Jingfeng Pharmaceutical
CSPC Hunan Jingfeng Pharmaceutical Co., Ltd. manufactures and sells chemical drugs and biological agents in China. The company offers sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmic devices and API products, as well as engages in the research and development of antitumor, cancer, and cardiovascular drugs; and distributed in the fields of cardiovascular disease, orthopedic pain disease, tumor disease, women and children.…
Full company profileHunan Jingfeng Pharmaceutical financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hunan Jingfeng Pharmaceutical annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.64B | 2.58B | 2.59B | 1.34B | 878M | 811M | 841M | 657M | 416M | 378M | 410M |
| Gross Profit | 2.08B | 2.03B | 1.95B | 806M | 547M | 488M | 635M | 459M | 261M | 238M | 265M |
| Operating Income | 441M | 258M | 255M | -908M | -1.12B | -136M | -68.3M | -173M | 204M | -27.9M | -16.3M |
| EBITDA | 600M | 417M | 422M | -738M | -962M | 28.1M | 18.4M | -116M | 231M | -16.2M | 12.0M |
| Net Income | 340M | 162M | 187M | -883M | -1.07B | -164M | -123M | -236M | 152M | -80.9M | 2.04M |
| EPS | 0.39 | 0.18 | 0.21 | -1.00 | -1.21 | -0.19 | -0.14 | -0.27 | 0.17 | -0.09 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 5.13B | 4.87B | 5.23B | 4.35B | 2.69B | 1.79B | 1.47B | 1.06B | 940M | 820M | 2.46B |
| Total Liabilities | 2.52B | 2.27B | 2.37B | 2.41B | 2.05B | 1.46B | 1.25B | 1.21B | 955M | 848M | 428M |
| Shareholders' Equity | 2.39B | 2.38B | 2.48B | 1.59B | 520M | 306M | 178M | -49.5M | 81.8M | 23.1M | 2.09B |
| Cash & Short-term Investments | 1.20B | 472M | 512M | 405M | 164M | 172M | 181M | 13.2M | 85.5M | 75.6M | 160M |
| Total Debt | 1.98B | 1.80B | 1.77B | 1.70B | 1.42B | 874M | 599M | 594M | 198M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 12.3M | 152M | 351M | 36.2M | -272M | 124M | 123M | 35.1M | -5.55M | 59.3M | - |
| Capital Expenditure | 253M | 303M | 171M | 114M | 96.0M | 38.1M | 13.5M | 10.4M | 1.38M | 4.57M | 80.8M |
| Free Cash Flow | -240M | -152M | 180M | -77.5M | -368M | 85.7M | 110M | 24.6M | -6.93M | 54.8M | -138M |
| Ratios | |||||||||||
| ROE | 14.2% | 6.8% | 7.5% | -55.6% | -205.5% | -53.4% | -68.9% | - | 186.2% | -349.5% | 0.1% |
| ROA | 6.6% | 3.3% | 3.6% | -20.3% | -39.7% | -9.1% | -8.3% | -22.3% | 16.2% | -9.9% | 0.1% |
| Net Profit Margin | 12.9% | 6.3% | 7.2% | -65.7% | -121.7% | -20.2% | -14.6% | -35.9% | 36.6% | -21.4% | 0.5% |
| Debt to Equity | 0.83x | 0.76x | 0.71x | 1.07x | 2.74x | 2.85x | 3.37x | - | 2.43x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hunan Jingfeng Pharmaceutical dividends
- Dividend yield
- 0.11%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 23, 2018
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 10.5M | 0.01 | - |
| 2024 | CNY 13.4M | 0.02 | 8.8% |
| 2023 | CNY 23.6M | 0.03 | - |
| 2022 | CNY 39.6M | 0.05 | - |
| 2021 | CNY 91.5M | 0.10 | - |
| 2020 | CNY 89.2M | 0.10 | - |
| 2019 | CNY 86.6M | 0.10 | - |
| 2018 | CNY 102M | 0.12 | 54.7% |
| 2017 | CNY 91.4M | 0.10 | 56.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 11:10 on Jun 23, 2016.
Who owns Hunan Jingfeng Pharmaceutical
- Insiders 51.42%
- Institutions 7.60%
- Public & others 40.97%
- Shares outstanding 1.76B
- Free float 1.10B
Hunan Jingfeng Pharmaceutical company profile
- Company name
- Hunan Jingfeng Pharmaceutical
- Ticker
- 000908.SHE
- ISIN
- CNE000000Y11
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Nov 18, 1998
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 463
- Fiscal year end
- December
- Address
- Shuangchuang Building, Changde, China, 415001
- Phone
- 86 21 6687 6520
- Website
- jfzhiyao.com
About Hunan Jingfeng Pharmaceutical
CSPC Hunan Jingfeng Pharmaceutical Co., Ltd. manufactures and sells chemical drugs and biological agents in China. The company offers sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmic devices and API products, as well as engages in the research and development of antitumor, cancer, and cardiovascular drugs; and distributed in the fields of cardiovascular disease, orthopedic pain disease, tumor disease, women and children. The company was formerly known as Hunan Jingfeng Pharmaceutical Co.,Ltd. and changed its name to CSPC Hunan Jingfeng Pharmaceutical Co., Ltd. in April 2026. The company was founded in 1998 and is headquartered in Changde, China.
Hunan Jingfeng Pharmaceutical management
3- Mr. Shulin LiuPresident & Non-Independent Director · born 1976
- Ms. Xuehong MaNon-Independent Director & Financial Director · born 1970
- Mr. Ce GuoBoard Secretary · born 1993